Bull Case

Amvuttra uptake accelerates in ATTR-CM and ATTR-PN, lifting revenue growth above peers and expanding operating leverage as launch costs are absorbed.

Earlier-line adoption and broader payer access reduce friction, allowing TBPH to outgrow smaller rare-disease peers with narrower commercial reach.

Pipeline execution in next-wave RNAi assets adds optionality, supporting multiple shots on goal and improving long-term revenue durability versus single-product peers.

Strong net cash and modest leverage preserve flexibility for launch investment and business development, limiting financing risk relative to more indebted biotech peers.

Base Case

Amvuttra continues to grow steadily, but normalization after the initial launch phase keeps revenue expansion solid rather than explosive versus larger rare-disease peers.

Operating margin improves gradually from the low-single-digit TTM level as commercial scale offsets R&D and SG&A, but profitability remains below mature biotech peers.

ATTR franchise concentration remains the main driver of results, so execution in one or two indications determines most of the upside and downside over the next 1–3 years.

Balance-sheet strength cushions volatility and supports continued investment, but interest coverage near 4x still leaves less room than cash-rich peers if growth slows.

Bear Case

Amvuttra growth decelerates materially if payer resistance, competitive therapies, or slower diagnosis reduce new patient starts versus better-diversified rare-disease peers.

Commercial leverage stalls, keeping operating margins near the current low level and limiting the path to sustained earnings power.

Pipeline setbacks or delayed label expansion reduce the second-leg growth story, increasing dependence on a single franchise and compressing valuation support.

Although net cash reduces near-term distress risk, weaker revenue momentum would still leave TBPH underperforming peers with broader product portfolios and stronger cash generation.

Overall Score

TBPH’s forward profile is anchored by Amvuttra-led growth and a strong balance sheet, with the base case remaining resilient versus peers despite concentration risk.